TearSolutions, LLC

TearSolutions has developed a proprietary synthetic fragment of lacritin, ‘Lacripep’.  Lacripep is water soluble, stable in human tears for 16 hr, and equipotent to lacritin in cell protection studies.  Our outsourcing development plan will complete preclinical, through phase II studies within 3 years for a potential product launch within 5 - 6 years.

Our mission is to develop a topical therapeutic for dry eye that addresses cause.The co-founder discovered lacritin, a tear protein deficient in dry eye and yet vital for normal eye tearing.  Preclinical studies reveal that a single topical dose of lacritin naturally promotes basal tearing without irritation that lasts for hours.  After multiple daily doses, elevated natural basal tearing is sustained one week later. Lacritin is also protective against inflammatory cytokines.  Corneal staining is reduced to background and lacrimal gland inflammation is diminished. No other tear protein, nor dry eye drug, displays these properties.

UVA Founders: Gordon W. Laurie, Ph.D.